Xenbase Image ID: 173262

Figure S4. Targeted injections to perturb endoderm contractility with MBS-T695A increases compliance and reduces aPKC localization. Related to Figure 5. (A) Tadpoles injected with either rhodamine dextran (RDA) or a constitutively active MBS-T695A. (B) MBST695A injected embryos exhibit reduced anterioposterior length (N= 14-19 embryos over two clutches) and (C) have higher rates of edema presentation per clutch (N = 2 clutches). These defects can be partially rescues by treatment with calyculin A during Stages 20-28. (D) Embryos expressing MBS-T695A in their anterior endoderm have increased compliance in the HFR (N = 13-14 embryos over two clutches). (E) Top panels show immunofluorescent staining of Stage 28 embryos with aPKC (green) and fixed injected RDA (cyan). Bottom panel shows manually segmented HPCs with aPKC in pseudocolor LUT. (F) Normalized apical intensity measurements of aPKC shows reduced intensity in HPCs with MBS-T695A injected into endoderm, which can be rescued with calyculin A treatment (N = 6-8 embryos over two clutches). Scale bar = 50 μm. Error bars represent mean ± SEM. * denotes p < 0.05; ** denotes p < 0.01; *** denotes p < 0.001. Image published in: Jackson TR et al. (2017) Copyright © 2017. Image reproduced with permission of the Publisher, Elsevier B. V. Larger Image Printer Friendly View

Return to previous page